Moderna
Last updated Jun 17, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
2
Clinical Programs
0
Confidence Coverage
77%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- HPV-related cancers
- Infectious Disease
- Vaccine
- COVID-19
Highest priority development: FDA AP — SANDIMMUNE (SUPPL)
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Moderna.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 77%
Active Signals
3
Investigate Priority
2
Opportunity Score
91
Buyer Quality
9 · Mid-Market
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJun 17, 2026Score 31E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice
Oncology · HPV-related cancers
- InvestigateJun 16, 2026Score 31NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273
Infectious Disease · COVID-19
- MonitorJun 17, 2026Score 29mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years
Infectious Disease · Vaccine
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — SANDIMMUNE (SUPPL)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — SANDIMMUNE (SUPPL)Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 31E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice
Oncology · HPV-related cancers
- InvestigateScore 31NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273
Infectious Disease · COVID-19
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Moderna right now?
- Which regulatory precedents should Moderna monitor in Oncology and HPV-related cancers?
- How does Emerging CD2 compare to the nearest competitive programs?
- What signals require immediate investigation for Moderna?
- Summarize the strategic implications of recent developments for Moderna.
- Where is the greatest uncertainty in Moderna's competitive positioning?